Assessors increasingly ask whether a trial measured what matters to patients. Patient-reported outcomes can strengthen a reimbursement case, but only if they were planned, validated and analysed with assessment in mind.
Why this has moved up the agenda
Under the EU HTA Regulation, patients and clinical experts are consulted during the joint clinical assessment scoping, which defines the population, intervention, comparator and outcomes to be examined. Commentary on the process describes a short consultation window on the draft scope, typically one to two weeks. Outcomes that patients regard as important but the trial did not capture are hard to add later.
What assessors look for in PRO data
A patient-reported outcome is useful only if it can be trusted.
- A validated instrument appropriate for the condition and population.
- Pre-specified analysis, consistent with the guidance on multiplicity, subgroup and post hoc analyses.
- Manageable missing data, since dropout in advanced disease can bias results.
- Clinical meaning: evidence that observed changes are large enough for patients to notice, not merely statistically significant.
- Generic utility measures where economic models require them.
Common weaknesses
Questionnaires added late to a protocol, secondary endpoints with no pre-specified analysis, and open-label designs where subjective outcomes are vulnerable to bias all weaken the case. In single-arm studies, patient-reported data are difficult to interpret without a comparator.
Building it in from the start
Engage patient organisations and clinicians before the protocol is final. Joint scientific consultation provides an opportunity to test whether the chosen outcomes would be accepted. Plan how PRO data will feed both the clinical assessment and the economic model, so that the same evidence serves regulators, HTA bodies and payers.
Linking outcomes to the economic case
Patient-reported outcomes often feed the economic model through utility values, so weaknesses in the clinical data can pass directly into the cost-effectiveness analysis. If quality-of-life data were collected with an instrument that cannot be mapped to a generic utility measure, the model may need to rely on external sources, which assessors may challenge.
Planning both uses together avoids that problem. Decide at the protocol stage which instruments will serve the clinical argument and which will serve the model, and confirm that the sample size and timing of assessments are adequate for each purpose. Consistency between the clinical and economic submissions is one of the clearest signs of a well-prepared dossier.
How PQRA helps
PQRA can help align clinical development plans with regulatory and HTA expectations, and review whether the outcomes planned for a programme are likely to support reimbursement discussions in Greece and the EU.
If you are planning a development programme and want the outcomes to count at assessment, Contact PQRA.


No responses yet